Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)
Introduction
Chronic obstructive pulmonary disease (COPD) is predicted to become the third most common cause of death and the fifth most common cause of disability in the word by 2020 (Lopez and Murray, 1998).
The airways inflammation and the increased production of reactive oxygen species in the lung play a key role in the pathogenesis of this widespread respiratory disease (Barnes, 2003, Paredi et al., 2002, MacNee, 2001). Although bronchoepitelial cells contain high levels of antioxidant to compete with such oxidants, in COPD, they are inadequate. Therefore, it is realized an oxidant-mediated epithelial injury that finish to damage the epithelial surface of airways by peroxidizing lipids, disrupting proteins and deoxyribonucleic acid (DNA; Brandolini et al., 2003, Kasielski and Nowak, 2001, Pinamonti et al., 1996).
Recent studies have shown an increase in inflammatory and oxidative stress markers such as Interleukin-6, Leukotriene B4 (LTB4), 8-isoprostane, hydrogen peroxide (H2O2) and ethane in breath condensate of COPD subjects (Biernacki et al., 2003, Carpagnano et al., 2003a, Carpagnano et al., 2003b, Dekhuijzen et al., 1996, Montuschi et al., 2000, Paredi et al., 2000). This new method to collect sample from airways, the breath condensate, has recently arouses interest in research and clinic for its simplicity, practicability, noninvasiveness and especially for the great acceptance by patients (Kharitonov and Barnes, 2001a, Kharitonov and Barnes, 2001b).
The inflammation and the oxidative stress further raise during periods of acute exacerbations of COPD that are known to represent the most common cause of hospitalization and of health care costs (Biernacki et al., 2003, Fletcher and Peto, 1977, Kanner et al., 2001). Also, the mucus hypersecretion, hallmark of COPD, seems to get worse during the exacerbations (Schreiber et al., 2002).
Notwithstanding the key role of mucous in aggravate airflow obstruction, the value of mucolytic therapy is unrecognized at a point that the European Respiratory Society and the American Thoracic Society COPD guidelines discouraged the use of mucolytic in treatment of patients with stable and/or acute COPD (American Thoracic Society Standards, 1995 guidelines; British Thoracic Society guidelines, 1997, Schreiber et al., 2002). Of late, the point of view of researchers and clinicians at this regard seems starting to change inasmuch as some thiol-containing mucolytic drugs (sodium 2-mercaptoethane sulphonate and N-acetylcysteine) showed associated with their therapeutical effect, anti-inflammatory and antioxidant capabilities (Gressier et al., 1994, Kasielski and Nowak, 2001).
Only recently also, the thioether group contained in carbocysteine lysine salt monohydrate (SCMC-Lys) has been found to have some capacities to reduce airways inflammation (Barnes, 2003, Pfeifer et al., 1997).
The purpose of the present work was to assess the inflammation and the oxidative stress in airways of COPD patients during an acute exacerbation of diseases and in stability. Furthermore, we studied the anti-inflammatory and antioxidant effects of SCMC-Lys in COPD patients measuring an inflammatory (Interleukine-6) and an oxidative stress marker (8-isoprostane) in their breath condensate before and after 6 months of SCMC-Lys administration.
Section snippets
Study population
We studied 40 ex-smoker patients with mild COPD (cigarette consumption 32±5 pack/years) and 15 nonsmoker healthy subjects with no history of lung disease (Table 1). All subjects were recruited from the Respiratory Disease Institute, University of Bari, and written informed consent was obtained from all subjects. The study was approved by the Institutional Ethics Committee. The diagnosis of COPD was based on GOLD Guidelines (Pauwels et al., 2001). All COPD patients were ex-smokers, had stopped
Results
All patients tolerated the SCMC-Lys without any complaints of side effects. The lung function parameters (FEV1, FVC), the blood gases and the plasmatic neutrophils and PCR showed an improvement in COPD patients hospitalized for acute exacerbation after 2 weeks of antibiotics but did not indicate any significant differences after treatment with SCMC-Lys (Table 2).
No amylase activity was detected in any exhaled breath condensate sample.
Discussion
This study showed significantly higher concentrations of 8-isoprostane and Interleukine-6 in the breath condensate of COPD subjects than in healthy controls, especially during an acute exacerbation of the disease. Both these markers presented a marked reduction after 6 months of daily administration of carbocysteine lysine salt monohydrate (SCMC-Lys) in COPD subjects. However, an improvement of lung function after mucolytic drug was not watched. Finally, a positive correlation was observed
Acknowledgement
Supported by Dompe' S-p.A., Research Center, via Campo di Pile, 67100, L'Aquila, Italy.
References (36)
- et al.
Effectiveness of carbocysteine lesine salt monohydrate on models of airway inflammation and hyperresponsiveness
Pharmacol. Res.
(1995) - et al.
S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction
Chest
(1976) - et al.
Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease
Respir. Med.
(2001) The oxidative stress and lung inflammation in airways disease
Eur. J. Pharmacol.
(2001)- et al.
Xantine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease
Free Radic. Biol. Med.
(1996) - et al.
Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease
Am. J. Respir. Crit. Care Med.
(2001) - et al.
Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lesine salt monohydrate: a multicenter, double-blind. Placebo-controlled trial
Respiration
(1996) American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
Am. J. Respir. Crit. Care Med.
(1995)Chronic obstructive pulmonary disease
N. Engl. J. Med.
(2000)New concepts in chronic obstructive pulmonary disease
Annu. Rev. Med.
(2003)
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbation
Thorax
Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD
Thorax
Statistics notes: measurement error
BMJ
IL-1β primes IL-8 activated human neutrophils for elastase release phospholipase D activity and calcium flux
J. Leukoc. Biol.
Carbocysteine lysine salt monohydrate (SCMC-LYS) is a selective scavenger of reactive oxygen intermediates
Eur. Cytokine Netw.
British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease
Thorax
Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis
Am. J. Respir. Crit. Care Med.
Interleukine-6 is increased in breath condensate of smokers
Eur. Respir. J.
Cited by (83)
Bronchiectasis
2023, Presse MedicaleThiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics
2019, Trends in Pharmacological SciencesGenetics in Asthma and COPD
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth Edition